Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Yoshiya TanakaHiroyuki IzutsuPublished in: Expert opinion on pharmacotherapy (2020)
Peficitinib has proven clinical efficacy in Asian patients (Japan, Korea, and Taiwan) with RA who have an inadequate response to conventional DMARDs. In Phase 3 trials, clinical improvements and prevention of joint destruction were demonstrated for both 100 mg and 150 mg once-daily peficitinib versus placebo, and treatment for up to 52 weeks was well tolerated. Safety signals, in particular the increased incidence of herpes zoster-related disease, appeared in line with other JAK inhibitors. Post-launch monitoring will establish the long-term safety and effectiveness of this drug, and further studies are necessary to determine its potential use in non-Asian populations.
Keyphrases
- rheumatoid arthritis
- clinical trial
- end stage renal disease
- randomized controlled trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- risk factors
- physical activity
- ankylosing spondylitis
- disease activity
- prognostic factors
- interstitial lung disease
- peritoneal dialysis
- systemic sclerosis
- idiopathic pulmonary fibrosis